ImmunoFree

Executive Summary

ImmunoFree is a private biotechnology company founded in 2018 and headquartered in San Diego, CA, with a mission to eliminate the need for lifelong immunosuppressive drugs in organ transplant recipients. Its proprietary stem cell-based therapy platform is designed to induce immune tolerance, enabling the recipient's immune system to accept the transplanted organ without chronic immunosuppression. This approach has the potential to dramatically improve patient quality of life by reducing the severe side effects and risks associated with lifelong immunosuppression, such as infections, malignancies, and organ damage. The company is currently in the preclinical stage, focusing on validating its platform in animal models and advancing toward an Investigational New Drug (IND) application with the FDA. ImmunoFree's technology represents a paradigm shift in transplant medicine, addressing a significant unmet need for approximately 100,000 organ transplant recipients annually in the US alone.

Upcoming Catalysts (preview)

• Q2 2027IND Filing for Lead Immuno-Tolerance Candidate60% success
• Q4 2026Preclinical Proof-of-Concept Data in Non-Human Primates75% success
• Q1 2027Strategic Partnership with Major Transplant Center for Clinical Development50% success